Iovance Therapeutics stock dropped 15% due to CFO departure and lowered revenue guidance.

From Nasdaq: 2025-06-27 18:57:00

Investors in biotech stock Iovance Therapeutics (NASDAQ: IOVA) saw shares drop 15% following the departure of CFO Jean-Marc Bellemin, effective July 10. Legal troubles and a setback with flagship drug Amtagvi contributed to the executive’s exit. Despite top-line growth, Iovance slashed product-revenue guidance for the year, raising concerns about its future performance. While risky, Amtagvi still shows promise, making Iovance a company to watch in the cancer space. Consider other investment options as Iovance Biotherapeutics may not be the best choice for potential growth based on analyst recommendations and historical returns.



Read more at Nasdaq: Why Iovance Biotherapeutics Stock Dove by Almost 15% This Week